Page last updated: 2024-09-03

marimastat and Prostatic Neoplasms

marimastat has been researched along with Prostatic Neoplasms in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (25.00)	18.2507
2000's	2 (50.00)	29.6817
2010's	1 (25.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Antonarakis, ES; Lin, J; Suzman, DL; Zahurak, ML; Zhou, XC	1
Barrett, M; Burnitz, MC; Dipierro, C; Eto, M; Gibson, JJ; Myers, C; Phelps, C; Read, P; Somlyo, AP; Somlyo, AV	1
Carducci, MA; DeWeese, TL; Eisenberger, MA; Laufer, M; Pili, R; Rosenbaum, E; Sinibaldi, V; Zahurak, M	1

Trials

2 trial(s) available for marimastat and Prostatic Neoplasms

Article	Year
Change in PSA velocity is a predictor of overall survival in men with biochemically-recurrent prostate cancer treated with nonhormonal agents: combined analysis of four phase-2 trials. Prostate cancer and prostatic diseases, 2015, Volume: 18, Issue:1 Topics: Aged; Benzamides; Biomarkers; Biomarkers, Tumor; Disease-Free Survival; Humans; Hydroxamic Acids; Imatinib Mesylate; Kinetics; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Piperazines; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Pyrimidines	2015
Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Jun-15, Volume: 11, Issue:12 Topics: Aged; Analysis of Variance; Arthralgia; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Humans; Hydroxamic Acids; Male; Metalloendopeptidases; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Time; Treatment Outcome	2005

Article

Year

Change in PSA velocity is a predictor of overall survival in men with biochemically-recurrent prostate cancer treated with nonhormonal agents: combined analysis of four phase-2 trials.

Prostate cancer and prostatic diseases, 2015, Volume: 18, Issue:1

Topics: Aged; Benzamides; Biomarkers; Biomarkers, Tumor; Disease-Free Survival; Humans; Hydroxamic Acids; Imatinib Mesylate; Kinetics; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Piperazines; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Pyrimidines

2015

Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Jun-15, Volume: 11, Issue:12

Topics: Aged; Analysis of Variance; Arthralgia; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Inhibitors; Humans; Hydroxamic Acids; Male; Metalloendopeptidases; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Time; Treatment Outcome

2005

Other Studies

2 other study(ies) available for marimastat and Prostatic Neoplasms

Article	Year
Rho kinase and matrix metalloproteinase inhibitors cooperate to inhibit angiogenesis and growth of human prostate cancer xenotransplants. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2003, Volume: 17, Issue:2 Topics: Amides; Animals; Aorta, Thoracic; Cell Division; Cell Line; Drug Synergism; Enzyme Inhibitors; Humans; Hydroxamic Acids; In Vitro Techniques; Intracellular Signaling Peptides and Proteins; Male; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Mice; Mice, SCID; Microscopy, Fluorescence; Myosin-Light-Chain Phosphatase; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Phosphoprotein Phosphatases; Phosphorylation; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Pyridines; Rabbits; rho-Associated Kinases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2003
Marimastat. BB 2516, TA 2516. Drugs in R&D, 1999, Volume: 1, Issue:2 Topics: Adult; Antineoplastic Agents; Colorectal Neoplasms; Drugs, Investigational; Female; Humans; Hydroxamic Acids; Male; Melanoma; Metalloendopeptidases; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Protease Inhibitors; Stomach Neoplasms	1999

Article

Year

Rho kinase and matrix metalloproteinase inhibitors cooperate to inhibit angiogenesis and growth of human prostate cancer xenotransplants.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2003, Volume: 17, Issue:2

Topics: Amides; Animals; Aorta, Thoracic; Cell Division; Cell Line; Drug Synergism; Enzyme Inhibitors; Humans; Hydroxamic Acids; In Vitro Techniques; Intracellular Signaling Peptides and Proteins; Male; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Mice; Mice, SCID; Microscopy, Fluorescence; Myosin-Light-Chain Phosphatase; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Phosphoprotein Phosphatases; Phosphorylation; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Pyridines; Rabbits; rho-Associated Kinases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays

2003

Marimastat. BB 2516, TA 2516.

Drugs in R&D, 1999, Volume: 1, Issue:2

Topics: Adult; Antineoplastic Agents; Colorectal Neoplasms; Drugs, Investigational; Female; Humans; Hydroxamic Acids; Male; Melanoma; Metalloendopeptidases; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Protease Inhibitors; Stomach Neoplasms

1999